收费全文 | 106795篇 |
免费 | 9135篇 |
国内免费 | 3751篇 |
耳鼻咽喉 | 365篇 |
儿科学 | 1566篇 |
妇产科学 | 1308篇 |
基础医学 | 7196篇 |
口腔科学 | 1377篇 |
临床医学 | 10151篇 |
内科学 | 16728篇 |
皮肤病学 | 1399篇 |
神经病学 | 2837篇 |
特种医学 | 1187篇 |
外国民族医学 | 15篇 |
外科学 | 3952篇 |
综合类 | 14397篇 |
现状与发展 | 11篇 |
一般理论 | 3篇 |
预防医学 | 9558篇 |
眼科学 | 855篇 |
药学 | 35280篇 |
43篇 | |
中国医学 | 4378篇 |
肿瘤学 | 7075篇 |
2024年 | 340篇 |
2023年 | 1623篇 |
2022年 | 3132篇 |
2021年 | 4115篇 |
2020年 | 3712篇 |
2019年 | 3636篇 |
2018年 | 3761篇 |
2017年 | 3837篇 |
2016年 | 3935篇 |
2015年 | 4112篇 |
2014年 | 6962篇 |
2013年 | 10296篇 |
2012年 | 7257篇 |
2011年 | 7533篇 |
2010年 | 5986篇 |
2009年 | 5358篇 |
2008年 | 5364篇 |
2007年 | 5333篇 |
2006年 | 4715篇 |
2005年 | 4185篇 |
2004年 | 3503篇 |
2003年 | 2950篇 |
2002年 | 2299篇 |
2001年 | 2139篇 |
2000年 | 1725篇 |
1999年 | 1479篇 |
1998年 | 1252篇 |
1997年 | 1163篇 |
1996年 | 971篇 |
1995年 | 848篇 |
1994年 | 749篇 |
1993年 | 618篇 |
1992年 | 674篇 |
1991年 | 575篇 |
1990年 | 439篇 |
1989年 | 380篇 |
1988年 | 340篇 |
1987年 | 344篇 |
1986年 | 249篇 |
1985年 | 313篇 |
1984年 | 241篇 |
1983年 | 171篇 |
1982年 | 194篇 |
1981年 | 153篇 |
1980年 | 120篇 |
1979年 | 108篇 |
1978年 | 101篇 |
1977年 | 86篇 |
1976年 | 85篇 |
1975年 | 79篇 |
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献Methods: Animals were given indomethacin or SC-560 p.o., and the intestinal mucosa was examined 24 h later.
Results: Indomethacin caused hemorrhagic lesions in the small intestine, accompanied with an increase in intestinal motility, bacterial invasion and inducible nitric oxide synthase (iNOS) activity, as well as the expression of COX-2 mRNA in the mucosa. Although SC-560 did not cause any damage, this agent caused intestinal hypermotility, the bacterial invasion and the upregulation of COX-2 expression. The mucosal PGE
Conclusion: These results suggest that COX-2 expression in the intestinal mucosa following the administration of indomethacin is associated with intestinal hypermotility and bacterial invasion. The intestinal hypermotility caused by COX-1 inhibition may be a key to COX-2 expression after administration of NSAIDs and their intestinal ulcerogenic properties. 相似文献